0001209191-20-059104.txt : 20201118
0001209191-20-059104.hdr.sgml : 20201118
20201118163036
ACCESSION NUMBER: 0001209191-20-059104
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201116
FILED AS OF DATE: 20201118
DATE AS OF CHANGE: 20201118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hoppenot Herve
CENTRAL INDEX KEY: 0001596492
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12400
FILM NUMBER: 201325492
MAIL ADDRESS:
STREET 1: C/O INCYTE CORPORATION-EXPERIMENTAL STN.
STREET 2: ROUTE 141 & HENRY CLAY RD., BLDG. E336
CITY: WILMINGTON
STATE: DE
ZIP: 19880
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INCYTE CORP
CENTRAL INDEX KEY: 0000879169
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 943136539
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: 3024986700
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE CORP
DATE OF NAME CHANGE: 20030318
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE GENOMICS INC
DATE OF NAME CHANGE: 20000710
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930902
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-16
0
0000879169
INCYTE CORP
INCY
0001596492
Hoppenot Herve
1801 AUGUSTINE CUT-OFF
WILMINGTON
DE
19803
1
1
0
1
Chairman / CEO
President
Common Stock
2020-11-16
4
A
0
7225
0.00
A
271306
D
Common Stock
66234
I
By GRAT
Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded.
Including the Performance Stock Units earned on November 16, 2020 this includes an aggregate of 120,195 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.
On June 15, 2018, the reporting person contributed 103,033 shares to a grantor retained annuity trust (GRAT). On June 17, 2019, 20,407 shares
were distributed by the GRAT to the reporting person in accordance with the terms of the GRAT and continue to be reported in this Form 4 as
directly owned. In addition, on June 2, 2020 an additional 16,392 were distributed by the GRAT to the reporting person in accordance with the
terms of the GRAT and continue to be reported in this Form 4 as directly owned.
/s/ Herve Hoppenot
2020-11-18